News BridgeBio’s $250m raise heads latest biotech financings BridgeBio Pharma has raised $250 million from the sale of nine million shares that is earmarked for the commercial launch of its acoramidis drug for transthyretin amyloido
News UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face